What is Qinlock and why it matters
Qinlock is the brand name for the drug ipatasertib, a selective inhibitor of the protein kinase AKT. It was developed to target tumors that depend on the PI3K‑AKT‑mTOR signaling pathway, most notably certain subtypes of breast cancer. The drug was approved by the FDA in 2024 for use in patients with metastatic triple‑negative breast cancer that has progressed after endocrine therapy or chemotherapy and whose tumors show high AKT1‑mutated or PIK3CA‑mutated status.
[1]
How Qinlock works in breast cancer
Ipatasertib blocks the activity of AKT, a key enzyme that promotes cancer cell growth, survival, and metabolism. By inhibiting AKT, Qinlock interrupts these pro‑tumor signals, making it harder for cancer cells to proliferate and spread. The drug is often combined with other treatments, such as the HER2‑targeted therapy trastuzumab, to enhance efficacy.
[1]
What clinical data backs Qinlock?
The pivotal phase III trial, AXIS, compared ipatasertib plus fulvestrant versus fulvestrant alone in 1,000+ patients with metastatic breast cancer. The combination improved progression‑free survival by about 4.5 months (median 5.5 vs 1.0 month) and overall survival by roughly 7 months in the targeted population. A separate phase II study with carboplatin and paclitaxel showed a 40‑percent objective response rate in patients with AKT1‑mutated disease. These results earned the drug accelerated approval.
[1]
Who can receive Qinlock?
Eligible patients are adults with metastatic triple‑negative breast cancer whose tumors have a confirmed AKT1 mutation, PIK3CA mutation, or high PTEN loss. The drug must be given after progression on at least one line of endocrine therapy or chemotherapy. A companion diagnostic test (a tumor DNA assay) is required to confirm the biomarker status.
[1]
Dosing and administration details
The approved dose is 125 mg of ipatasertib taken orally once daily, with a 1‑week on/3‑week off schedule. The drug can be taken with or without food. Patients are monitored for toxicity every two weeks during the first two cycles, then monthly. Common monitoring parameters include blood pressure, renal function, and complete blood counts.
[1]
What side effects should patients be aware of?
The most frequent adverse events are diarrhea, fatigue, nausea, and hyperglycemia. Severe side effects such as grade 3‑4 neutropenia, hypertension, and hypokalemia occur in a minority of patients. Routine blood glucose monitoring and antihypertensive therapy are advised for those with pre‑existing metabolic issues.
[1]
Are there competitor or biosimilar options?
Other AKT inhibitors, such as capivasertib (JAK‑Z) and MK 2206, are in various development stages but none have matched Qinlock’s approved indication for metastatic triple‑negative breast cancer. No biosimilar exists yet, and the market is still dominated by small‑molecule kinase inhibitors rather than biologics.
[1]
Patent status and exclusivity
Ipatasertib is protected by patents covering its chemical structure, formulation, and specific therapeutic uses. The primary patent covering the drug’s use in metastatic breast cancer expires in 2032, granting the manufacturer a 9‑year exclusivity window from the 2024 approval date. This period shields the product from direct generic competition but allows for biosimilar development after the exclusivity lapses.
[1]
Pricing, insurance, and patient assistance
Qinlock carries a list price of roughly $12,000 per month. Most commercial insurers cover the drug under their oncology benefits, often requiring prior authorization. The manufacturer offers a patient assistance program for qualifying low‑income patients, which includes copay reductions and medication delivery.
[1]
What’s next for Qinlock?
Ongoing trials are evaluating Qinlock in combination with immunotherapies (e.g., pembrolizumab) and in earlier lines of therapy. A phase III study in HER2‑positive metastatic breast cancer aims to assess whether ipatasertib can improve outcomes when paired with trastuzumab and pertuzumab. Results are expected by 2026.
[1]